Drugs / pelitinib
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00098501 | Oct 2004 → Oct 2007 | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00067548 | ? → Jan 2005 | non-small cell lung carcinoma | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00072748 | ? → Oct 2004 | colonic neoplasm, rectal neoplasm | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pelitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00098501 ↗ |
| Known as | EKB-569 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00067548 ↗ |
| Known as | WAY-EKB-569 | ChEMBL registry synonym — accepted as the source's own label CHEMBL607707 ↗ |
| Action | Inhibit | “Epidermal growth factor receptor erbB1 inhibitor” CHEMBL607707 ↗ |
| Modality | Small molecule | — CHEMBL607707 ↗ |
| Route | Oral | “administered orally” NCT00067548 ↗ |
| Target | EGFR | “Epidermal growth factor receptor erbB1 inhibitor” CHEMBL607707 ↗ |